• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • ANNUAL GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Akari TX

Akari TX / May 1, 2025

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development – Oncology

Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record …

[Read more...] about Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development – Oncology

Akari TX / April 22, 2025

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video hereBOSTON and LONDON – …

[Read more...] about Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Akari TX / April 22, 2025

Welcome from Abizer Gaslightwala, President and CEO

…

[Read more...] about Welcome from Abizer Gaslightwala, President and CEO

Akari TX / April 16, 2025

Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer …

[Read more...] about Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Akari TX / March 20, 2025

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and …

[Read more...] about Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

« Previous Page
Next Page »

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.